Next 10 |
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...
2024-05-05 14:25:00 ET There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common th...
2024-05-05 09:45:00 ET Summary Lantheus Holdings just posted strong Q1 numbers, exceeding expectations and confirming its attractive investment potential. The firm is delivering solid revenue growth, impressive free cash flow, and management raised FY2024 guidance significantly. ...
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
2024-05-03 11:15:29 ET Summary Swiss Helvetia Fund is trading at a 16% discount to NAV and could be a potential takeover target in the future. The ETF has concentrated holdings in strong businesses with high dividends, making it attractive for dividend investors. The overall d...
2024-05-03 09:53:55 ET Summary TG Therapeutics beat first quarter revenue expectations and raised the full-year revenue guidance by $40 million at the mid-point. Work on the subcutaneous version of Briumvi continues and could represent the next step for increased long-term growth ...
2024-05-03 07:00:00 ET Summary The stock market is unpredictable, and even professionals struggle to understand it. Stocks have historically been the best-performing asset, but short-term returns are influenced by sentiment, momentum, and luck. According to JPMorgan, 96% of st...
2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...
2024-05-02 07:46:21 ET Novartis ( NYSE: NVS ) has agreed to acquire cancer drugmaker Mariana Oncology for an upfront payment of $1B and an additional $750M in milestone payments.... Read the full article on Seeking Alpha For further details see: Novartis to buy Maria...
2024-04-30 12:18:17 ET More on AstraZeneca, GSK, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy AstraZeneca: Strong In A Weak Market GSK Q1 2024 Earnings Preview Ast...
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
NYSE Market:
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – ...
2024-05-05 14:25:00 ET There are many reasons to invest in excellent dividend stocks. Such investments are often worth the trouble regardless of whether you're investing for the dividend, or for making capital gains from the robust business (always a laudable goal). But here's the common th...
The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...